{"id":"W3213050308","doi":"10.1182/bloodadvances.2021005794","title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"National Cancer Institute; Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Bendamustine; Hazard ratio; Internal medicine; Cohort; Confidence interval; Rituximab; Clinical endpoint; Randomized controlled trial; Oncology; Surgery; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01604018,0.0005613281,0.001313979,0.0006492888,0.0002804777,0.001626829,0.0009759705,0.0005569838,0.001746121],"category_scores_gemma":[0.01142049,0.0003809702,0.001453025,0.001221431,0.0003414527,0.001221811,0.0009935801,0.001608036,0.0004014581],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009923833,"about_ca_system_score_gemma":0.001876858,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002715291,"about_ca_topic_score_gemma":0.005359035,"domain_scores_codex":[0.997035,0.001261582,0.0004156523,0.000342496,0.0007720136,0.0001732687],"domain_scores_gemma":[0.9864839,0.004179828,0.002919009,0.002233804,0.002237591,0.001945967],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1040694,0.00211746,0.1947304,0.002414986,0.006329495,0.0006133353,0.000654394,0.003710182,0.009658944,0.001819627,0.06068251,0.6131992],"study_design_scores_gemma":[0.04117602,0.02238199,0.5646767,0.0017749,0.01280905,0.003548896,0.0002867213,0.004263767,0.004667305,0.002156664,0.342034,0.000224027],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8300959,0.08850146,0.006738903,0.007425321,0.001046259,0.001213487,0.04979802,0.000467714,0.01471295],"genre_scores_gemma":[0.8043966,0.04280878,0.01131929,0.007058489,0.001600616,0.001852142,0.1260172,0.0003056525,0.004641113],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01604018,"threshold_uncertainty_score":0.08482963,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03337199370905094,"score_gpt":0.2962263346243567,"score_spread":0.2628543409153058,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}